Upcoming FDA Advisory Committee meetings (sourced live from the Federal Register API), plus biotech-tagged tickers in the Framler universe with earnings in the next 30 days. Free, refreshed every 2 hours. Each ticker links to its full Framler analysis with Phase 3 trial scoring and pharma-stage classification.
FDA Advisory Committee meetings
Federal Register notices from the last 30 days. AdCom reviews precede most NDA / BLA approval decisions; binary outcomes for the sponsor.
Meeting 2026-10-30· Dermatologic and Ophthalmic Drugs Advisory Committee
Dermatologic and Ophthalmic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-New Drug Application (NDA) 219694 for Atropine Sulfate Ophthalmic Solution, 0.01%
The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee (the Committee). The general function of the Committee is to provide advice and rec…
Meeting 2026-11-19· Microbiology Devices Panel of the Medical Devices Advisory Committee
Microbiology Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Pathogen-Agnostic Sequencing
The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Microbiology Devices Panel of the Medical Devices Advisory Committee (the Committee). The general function of the Committee is to provid…
Meeting 2026-10-01· Vaccines and Related Biological Products Advisory Committee
Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-2027 Southern Hemisphere Influenza Virus Vaccines
The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Vaccines and Related Biological Products Advisory Committee (the Committee). The general function of the Committee is to provide advice …
Pre-revenue biotech can\'t be scored on traditional fundamentals (P/E, FCF, revenue growth). Framler runs a dedicated pharma-signal factor that ingests ClinicalTrials.gov trial state (Phase 1 / 2 / 3 / 4 + amendment count + completion proximity), classifies pharma stage (pre-revenue / early-revenue / growth / profitable), and weights the composite accordingly. NDA / BLA approval probability is computed from comparables across the trial database.